Uses of Finatas 5

1 Finatas 5 tablet contains 5mg Finasteride Ph.Eur and other excipients. Finasteride is an azasteroid that inhibits the iso type 2 alpha-reductase, the enzyme that converts testosterone to a more active substance than dihydrotestosterone. Therefore, the drug has anti-androgenic properties. Finasteride is a drug that inhibits the action of the male hormone testosterone. The process of prostate enlargement in prostatic hyperplasia is directly dependent on DHT (which is its main androgen hormone). Finasteride has the ability to inhibit the enzyme needed for the production of DTH, thereby reducing the concentration of DHT in the blood and tissues, helping the prostate shrink.
At an oral dose of 5mg/day, Finasteride helps treat symptoms of urinary tract disorders caused by benign prostatic hypertrophy. The response to the drug can be delayed, so treatment for 6 months or more is required to achieve the desired effect.
Finatas 5 is used to treat benign prostatic hypertrophy in order to reduce the volume of the enlarged prostate and improve symptoms. Thereby, the drug reduces the risk of acute urinary retention and the need for surgery.
Contraindications to using Finatas 5:
People with increased hypersensitivity to ingredients and active ingredients in the drug; Children under 18; Pregnant women and nursing mothers.

How to use: Orally, you can take Finatas 5 with or without food. Patients should take the tablet whole, not divided or crushed.
Dosage:
Adults: 1 tablet 5mg/day. Finatas 5 can be used alone or in combination with the alpha blocker doxazosin. Although early symptoms can be seen to improve, it is best to treat for a minimum of 6 months to assess whether treatment has been effective. After that, the treatment should continue to be prolonged; Elderly: No need to change the dose; Patients with renal impairment: No dose change is required even with varying degrees of renal impairment (creatinine clearance less than 9ml/min); Patients with hepatic impairment: There are no guidelines for the use of Finatas 5; Children: Contraindicated. According to the survey, there have been patients who used single doses of Finasteride 5mg to 400mg and multiple doses of Finasteride 5mg to 80mg/day without side effects. Rarely, patients who overdosed have experienced chest pain, nausea, irregular heartbeat, feeling light-headed, or fainting.
In case of patient overdose, treatment should be symptomatic and supportive. At the same time, it is necessary to carefully monitor the patient and consider the possibility of multidrug toxicity for appropriate interventions. Recommended measures usually include induction of vomiting and gastric lavage.
If a dose of Finatas 5 is forgotten, the patient must not arbitrarily double the dose to make up for the missed dose. Instead, patients should consult their doctor to receive appropriate advice when taking the drug.

Overall, Finatas 5 is well tolerated. In clinical studies, patients using Finasteride 5mg/day for 4 years may experience some side effects such as: Decreased libido, ejaculation disorder, impotence, decreased ejaculate volume, sensitive breasts, enlarged breasts, rash, hypersensitivity reactions (testicular pain, itchy skin, urticaria, swelling of the lips and face) ... When experiencing side effects related to the drug, the patient should report it immediately to the doctor. doctor for advice on proper management.

Some notes for patients to remember before and while taking Finatas 5:
Patients with large residual urine volume or severely reduced urine flow should be carefully monitored to find an obstructive pathology urinary tract; Before taking Finatas 5, it is necessary to rule out the following diseases: Urinary tract obstruction, malignancy, spastic disease, infection, prostate cancer, myasthenia gravis or other neurological diseases; Use caution when using Finatas 5 in patients with liver failure; The benefits of Finatas 5 for prostate cancer have not been studied. A digital rectal exam and other evaluations for prostate cancer should be performed prior to initiating treatment with Finasteride 5mg and periodically thereafter; Patients with galactose intolerance, glucose-galactose malabsorption or Lapp lactase deficiency should not use Finatas 5; Finatas 5 is contraindicated in women who are pregnant or of childbearing potential because the drug can cause abnormalities of the external genitalia of the baby boy when used in pregnant women. Pregnant women should also not handle broken or crushed Finasteride 5mg tablets because it increases the absorption of Finasteride and poses a potential risk to a male fetus; Finatas 5 should not be used in lactating women because the risk of drug effects on nursing mothers is unknown; Finatas 5 may affect PSA test results; Patients should notify their doctor immediately if there are any changes in the breast while taking Finatas 5 such as: Breast pain, breast enlargement, tumor appearance, nipple discharge.

Drug interactions can have some adverse effect on the effectiveness of the treatment or increase the side effects of the drug. To date, there is no information on clinically important drug interactions with Finatas 5. This drug does not significantly affect the cytochrome P450 enzyme system. Drugs that have been tested in humans such as digoxin, propranolol, warfarin, glibenclamide, theophylline and antipyrine have not had clinically significant interactions with this drug.
Finatas 5 tablets are also used concurrently with ACE inhibitors, beta blockers, alpha blockers, calcium channel blockers, H2 blockers, diuretics, cardiac nitrates, HMG inhibitors - CoA reductase, non-steroidal anti-inflammatory drugs (including aspirin, paracetamol), quinolones, benzodiazepines,... all have no clinically significant interactions.
When using Finatas 5, patients should carefully read the above instructions and strictly follow the doctor's instructions. If you have any questions or experience unusual symptoms, you should consult your doctor. Patients should not stop taking the medicine or change the dose on their own without the permission of the doctor.